Stock page
Clywedog Therapeutics Holdings Inc (CLYD)
Clywedog Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule modulators that target key signaling and gene regulation pathways with potential to halt or reverse the development and progression of metabolic diseases. It specializes in the development of next-generation inhibitors of menin for the treatment of type 2 (T2) diabetes and obesity and the prevention and treatment of type 1 (T1) diabetes. The company is developing a next-generation inhibitor of tyrosine kinase 2 (TYK2) for the treatment and prevention of T1 diabetes. Its pipeline includes CLY-101 and CLY-201.
Quote snapshot
$0.00
Daily change: —
ExchangeNAS
Updated2026-05-09T04:32:47.397064Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|